SCHEMBL23744656

SCHEMBL23744656

COc1ccc2nc(N3CCN[C@H](C)C3)sc2c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.55
TP53 P04637 6/20 0.55
LMNA P02545 1/20 0.55
TSHR P16473 2/20 0.53
SCN4A P35499 2/20 0.52
SCN9A Q15858 2/20 0.52
HCRTR2 O43614 3/20 0.51
HCRTR1 O43613 2/20 0.51
PDE10A Q9Y233 1/20 0.51
NPC1 O15118 4/20 0.49
RAB9A P51151 4/20 0.49
PKM P14618 1/20 0.49
TDP1 Q9NUW8 1/20 0.49
CYP2C9 P11712 3/20 0.48
CYP2C19 P33261 3/20 0.48
CYP1A2 P05177 3/20 0.48
KMT2A Q03164 2/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
CYP2D6 P10635 2/20 0.48
CYP3A4 P08684 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30345583 0.86 MAPT (0.56) MAPTTP53LMNATSHRHCRTR2
SCHEMBL30345573 0.86 MAPT (0.56) MAPTTP53LMNATSHRHCRTR2
SCHEMBL23744748 0.86 MAPT (0.56) MAPTTP53LMNATSHRHCRTR2
SCHEMBL23744760 0.86 MAPT (0.56) MAPTTP53LMNATSHRHCRTR2
SCHEMBL2708042 0.84 SCN4A (0.71) MAPTTP53LMNATSHRSCN4A
SCHEMBL19617607 0.83 NPC1 (0.61) MAPTTP53LMNASCN4ASCN9A
SCHEMBL19617634 0.83 NPC1 (0.61) MAPTTP53LMNASCN4ASCN9A
SCHEMBL10219152 0.83 NPC1 (0.60) MAPTHCRTR2HCRTR1NPC1RAB9A
SCHEMBL10219151 0.83 NPC1 (0.60) MAPTHCRTR2HCRTR1NPC1RAB9A
SCHEMBL19617818 0.83 NPC1 (0.61) MAPTTP53LMNASCN4ASCN9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4100410-B1 MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE NEUROCRINE BIOSCIENCES INC (US) 2026-04-22 EP disclosed
US-20230129359-A1 MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE NEUROCRINE BIOSCIENCES, INC. 2023-04-27 US disclosed
US-20230129359-A1 MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE NEUROCRINE BIOSCIENCES, INC. 2023-04-27 US disclosed
US-20230129359-A1 MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE NEUROCRINE BIOSCIENCES, INC. 2023-04-27 US disclosed
WO-2021158698-A1 MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE NEUROCRINE BIOSCIENCES, INC. (US) 2021-08-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230129359-A1 MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE CHRM4, CHRM2, CHRM5 MAPT 1187/4885TP53 2987/4885LMNA 4283/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.